NO963918L - Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav - Google Patents

Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav

Info

Publication number
NO963918L
NO963918L NO963918A NO963918A NO963918L NO 963918 L NO963918 L NO 963918L NO 963918 A NO963918 A NO 963918A NO 963918 A NO963918 A NO 963918A NO 963918 L NO963918 L NO 963918L
Authority
NO
Norway
Prior art keywords
peptides derived
tumor rejection
isolated peptides
complexes
precursor mage
Prior art date
Application number
NO963918A
Other languages
English (en)
Other versions
NO963918D0 (no
Inventor
Cornelis J M Melief
M W Visseren
W M Kast
Pierre Van Der Bruggen
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of NO963918D0 publication Critical patent/NO963918D0/no
Publication of NO963918L publication Critical patent/NO963918L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Oppfinnelsen beskriver peptider som er avledet fra tumor-rejeksjonsantigenforløper MAGE-2. Disse peptider binder til HLA-A2-molekyler, og presenterer dermed kom- plekser som frembringer cytolytisk T-celleproduksjon. De resulterende "CTLer" er spesifikke for komplekser av HLA- A2 og peptidet. Kompleksene kan anvendes for å fremstille monoklonale antistoff. De produserte cytolytiske T-celler kan anvendes innen området immunoterapi, såsom adoptiv overføring.
NO963918A 1994-03-24 1996-09-19 Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav NO963918L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,188 US5554724A (en) 1994-03-24 1994-03-24 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
PCT/US1995/003535 WO1995025530A1 (en) 1994-03-24 1995-03-21 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof

Publications (2)

Publication Number Publication Date
NO963918D0 NO963918D0 (no) 1996-09-19
NO963918L true NO963918L (no) 1996-11-20

Family

ID=22810016

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963918A NO963918L (no) 1994-03-24 1996-09-19 Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav

Country Status (17)

Country Link
US (3) US5554724A (no)
EP (1) EP0810870B1 (no)
JP (1) JP3360137B2 (no)
CN (1) CN1149257A (no)
AT (1) ATE201214T1 (no)
AU (1) AU682597B2 (no)
CA (1) CA2186006A1 (no)
DE (1) DE69520959T2 (no)
DK (1) DK0810870T3 (no)
ES (1) ES2158943T3 (no)
FI (1) FI963780A (no)
GR (1) GR3036320T3 (no)
NO (1) NO963918L (no)
NZ (2) NZ283561A (no)
PT (1) PT810870E (no)
WO (1) WO1995025530A1 (no)
ZA (1) ZA952375B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
WO1997035035A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
AU732468B2 (en) * 1997-06-23 2001-04-26 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
CA2336486A1 (en) 1998-07-28 2000-02-10 Kyogo Itoh Hla-a2 restricted tumor antigen peptide originated from sart-1
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
ATE494387T1 (de) * 2001-11-07 2011-01-15 Mannkind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
PL1620456T3 (pl) 2003-04-18 2014-06-30 Ose Pharma Int Sa Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
KR20140016315A (ko) 2011-03-07 2014-02-07 크리에이티브 네일 디자인 인코포레이티드 Uv-경화성 미용 손톱 코팅제를 위한 조성물 및 방법
CN104271612B (zh) 2012-03-15 2017-02-22 埃克森美孚化学专利公司 聚乙烯的氧整理
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
JP3360137B2 (ja) 2002-12-24
ZA952375B (en) 1995-12-15
US6063900A (en) 2000-05-16
EP0810870A4 (en) 1998-11-25
CN1149257A (zh) 1997-05-07
US5554724A (en) 1996-09-10
FI963780A0 (fi) 1996-09-23
US6147187A (en) 2000-11-14
NZ329695A (en) 2000-05-26
WO1995025530A1 (en) 1995-09-28
JPH10502329A (ja) 1998-03-03
EP0810870A1 (en) 1997-12-10
ES2158943T3 (es) 2001-09-16
NZ283561A (en) 1998-04-27
AU2189395A (en) 1995-10-09
PT810870E (pt) 2001-09-28
AU682597B2 (en) 1997-10-09
CA2186006A1 (en) 1995-09-28
EP0810870B1 (en) 2001-05-16
DK0810870T3 (da) 2001-07-23
FI963780A (fi) 1996-09-23
GR3036320T3 (en) 2001-11-30
DE69520959T2 (de) 2002-03-28
ATE201214T1 (de) 2001-06-15
DE69520959D1 (de) 2001-06-21
NO963918D0 (no) 1996-09-19

Similar Documents

Publication Publication Date Title
NO963918L (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
Weksler et al. Alterations of the immune system in thymic malignancies
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
ATE183195T1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
WO1999004265A3 (en) Cancer associated nucleic acids and polypeptides
EP0724456A4 (en) ANTIBODIES AGAINST CD40
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
GR3026219T3 (en) Mouse monoclonal antibodies
EP0739350A4 (en) LIGAND FIXING FAS ANTIGEN
EP0073953A3 (en) Monoclonal antibodies to cell surface antigens of human renal cancer
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
CA2045552A1 (en) Cancer related haptoglobin
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
PT996636E (pt) Antigenio ha-1
WO2004011483A3 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
AU5990100A (en) ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
Martyre et al. Characterization and Purification of Rauscher Leukemia-Associated Transplantation Antigens
SI1027375T1 (sl) Anti-idiotipska monoklonska protitelesa, njihova uporaba v aktivni imunoterapiji malignih tumorjev in sestavki, ki jih vsebujejo
GR890100333A (en) Antihuman antigen antibodies
AU2003204088A1 (en) Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application